JP2007504225A - 脂質系および使用方法 - Google Patents
脂質系および使用方法 Download PDFInfo
- Publication number
- JP2007504225A JP2007504225A JP2006525335A JP2006525335A JP2007504225A JP 2007504225 A JP2007504225 A JP 2007504225A JP 2006525335 A JP2006525335 A JP 2006525335A JP 2006525335 A JP2006525335 A JP 2006525335A JP 2007504225 A JP2007504225 A JP 2007504225A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- omega
- fatty
- fatty acid
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 120
- 238000000034 method Methods 0.000 title claims abstract description 61
- 235000016709 nutrition Nutrition 0.000 claims abstract description 89
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 69
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 claims abstract description 49
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 43
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims abstract description 43
- 229940033080 omega-6 fatty acid Drugs 0.000 claims abstract description 33
- 239000006014 omega-3 oil Substances 0.000 claims abstract description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 80
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 60
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 57
- 239000008103 glucose Substances 0.000 claims description 56
- 208000019553 vascular disease Diseases 0.000 claims description 46
- 102000004877 Insulin Human genes 0.000 claims description 40
- 108090001061 Insulin Proteins 0.000 claims description 40
- 229940125396 insulin Drugs 0.000 claims description 40
- 206010022489 Insulin Resistance Diseases 0.000 claims description 27
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 26
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 26
- 150000001720 carbohydrates Chemical class 0.000 claims description 26
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 claims description 26
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 26
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 25
- 229960004488 linolenic acid Drugs 0.000 claims description 24
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 21
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 20
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 20
- 235000020778 linoleic acid Nutrition 0.000 claims description 20
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 20
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 19
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 19
- 239000005642 Oleic acid Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 19
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 17
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 17
- 235000019485 Safflower oil Nutrition 0.000 claims description 13
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 13
- 239000003813 safflower oil Substances 0.000 claims description 13
- 235000005713 safflower oil Nutrition 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 12
- 239000000944 linseed oil Substances 0.000 claims description 12
- 235000021388 linseed oil Nutrition 0.000 claims description 12
- 230000035764 nutrition Effects 0.000 claims description 12
- 239000007903 gelatin capsule Substances 0.000 claims description 10
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 10
- 235000005687 corn oil Nutrition 0.000 claims description 9
- 239000002285 corn oil Substances 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims description 7
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 7
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims description 7
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 claims description 6
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 claims description 6
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 claims description 6
- 235000021297 Eicosadienoic acid Nutrition 0.000 claims description 6
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 claims description 6
- 235000021342 arachidonic acid Nutrition 0.000 claims description 6
- 229940114079 arachidonic acid Drugs 0.000 claims description 6
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 claims description 6
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims description 6
- BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 claims description 6
- 229940108623 eicosenoic acid Drugs 0.000 claims description 6
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 6
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 6
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 6
- 229960002733 gamolenic acid Drugs 0.000 claims description 6
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 5
- 235000004252 protein component Nutrition 0.000 claims description 5
- 239000008347 soybean phospholipid Substances 0.000 claims description 5
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 4
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000006492 vascular dysfunction Effects 0.000 claims description 3
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims 3
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims 2
- 230000000304 vasodilatating effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 97
- 239000000047 product Substances 0.000 description 68
- 238000009472 formulation Methods 0.000 description 44
- 239000003921 oil Substances 0.000 description 44
- 235000019198 oils Nutrition 0.000 description 43
- 239000002002 slurry Substances 0.000 description 39
- 235000005911 diet Nutrition 0.000 description 29
- 235000014113 dietary fatty acids Nutrition 0.000 description 29
- 239000000194 fatty acid Substances 0.000 description 28
- 229930195729 fatty acid Natural products 0.000 description 28
- 235000014633 carbohydrates Nutrition 0.000 description 27
- 150000004665 fatty acids Chemical class 0.000 description 26
- 206010012601 diabetes mellitus Diseases 0.000 description 25
- 235000013305 food Nutrition 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 230000037213 diet Effects 0.000 description 22
- 238000003756 stirring Methods 0.000 description 22
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000000463 material Substances 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 17
- 229910052500 inorganic mineral Inorganic materials 0.000 description 17
- 239000011707 mineral Substances 0.000 description 17
- 229940088594 vitamin Drugs 0.000 description 17
- 229930003231 vitamin Natural products 0.000 description 17
- 235000013343 vitamin Nutrition 0.000 description 17
- 239000011782 vitamin Substances 0.000 description 17
- 239000002775 capsule Substances 0.000 description 16
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 16
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 16
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 16
- 235000010755 mineral Nutrition 0.000 description 16
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 14
- 108010010803 Gelatin Proteins 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 239000008273 gelatin Substances 0.000 description 12
- 229920000159 gelatin Polymers 0.000 description 12
- 235000019322 gelatine Nutrition 0.000 description 12
- 235000011852 gelatine desserts Nutrition 0.000 description 12
- 239000003925 fat Substances 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 9
- 229960004484 carbachol Drugs 0.000 description 9
- 235000015872 dietary supplement Nutrition 0.000 description 9
- 235000013350 formula milk Nutrition 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 240000008042 Zea mays Species 0.000 description 8
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 7
- 235000005822 corn Nutrition 0.000 description 7
- 230000000378 dietary effect Effects 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 230000002641 glycemic effect Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000011573 trace mineral Substances 0.000 description 7
- 235000013619 trace mineral Nutrition 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 5
- 102000011632 Caseins Human genes 0.000 description 5
- 108010076119 Caseins Proteins 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- 150000004668 long chain fatty acids Chemical class 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000011785 micronutrient Substances 0.000 description 5
- 235000013369 micronutrients Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229960003080 taurine Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000011648 beta-carotene Substances 0.000 description 4
- 235000013734 beta-carotene Nutrition 0.000 description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 4
- 229960002747 betacarotene Drugs 0.000 description 4
- 229960004203 carnitine Drugs 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 235000011962 puddings Nutrition 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 230000004218 vascular function Effects 0.000 description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000004626 essential fatty acids Nutrition 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 235000021323 fish oil Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 235000021073 macronutrients Nutrition 0.000 description 3
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 3
- 229960001802 phenylephrine Drugs 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 235000011649 selenium Nutrition 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000220010 Rhode Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 235000019742 Vitamins premix Nutrition 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 238000000641 cold extrusion Methods 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000020774 essential nutrients Nutrition 0.000 description 2
- 150000002190 fatty acyls Chemical group 0.000 description 2
- 235000004426 flaxseed Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000019534 high fructose corn syrup Nutrition 0.000 description 2
- 238000009775 high-speed stirring Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000020888 liquid diet Nutrition 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000004865 vascular response Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000009027 Amelanchier alnifolia Nutrition 0.000 description 1
- 244000068687 Amelanchier alnifolia Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 235000009025 Carya illinoensis Nutrition 0.000 description 1
- 244000068645 Carya illinoensis Species 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940071162 caseinate Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 229940107218 chromium Drugs 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000020930 dietary requirements Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000015219 food category Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000028333 hypotonic response Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000011657 insulin resistance animal model Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 125000005481 linolenic acid group Chemical group 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pediatric Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
Abstract
Description
本発明の1つの実施態様は、脂質系を提供する。ω−3、ω−6およびω−9族各々からの長鎖多不飽和脂肪酸(LCPUFA)が、本脂質系に包含される。重量%に基づき、約0.25:1から約3:1のω−6 LCPUFAのω−3 LCPUFAに対する比率の範囲。重量%に基づき、約0.4:1から約3:1のω−9 LCPUFAのω−3 LCPUFAに対する比率の範囲。場合により、炭素原子数が12より多い飽和脂肪酸を、本脂質系に、全脂質100gあたり約47g未満のレベルでさらに加えてもよい。好ましくは、幾つかの油を併用して、上に明記したω−6脂肪酸対ω−3脂肪酸比およびω−9脂肪酸対ω−3脂肪酸比を達成することができる。
ここで用いる用語「脂質」は、水に不溶性である共通特性を有し、ならびにクロロホルムおよびエーテルなどの極性が低い有機溶媒により細胞から抽出することができる、生体系関連物質の不均質な群を一般に示す。
17から54%のα−リノレイン酸、17から21%のリノール酸、19から52%のオレイン酸、および47%未満の飽和脂肪酸を含む典型的な脂質系の一例は、これらの要件を満たすことができる。
本実施態様の脂質系は、経口的に許容されるあらゆる剤形およびこれらの組合せで投与することができる。こうした剤形の例には、例えば、咀しゃく錠、急速溶解性錠剤、発泡錠、再構成用粉末、エリキシル、液剤、溶液、懸濁液、乳剤、錠剤、多層錠、二層錠、カプセル、ソフトゼラチンカプセル、ハードゼラチンカプセル、カプレット、ロゼンジ、咀しゃくロゼンジ、ビード、粉末、顆粒、粒子、微粒子、分散性顆粒、カシェ剤、およびこれらの組合せが挙げられる。上の剤形の製造は、通常の当業者には周知である。
栄養製品用の炭水化物源の例には、トウモロコシ、タピオカ、米またはバレイショから得られる、蝋様または非蝋様形態での、加水分解物されたまたは無傷の、天然および/または化学変性デンプンが挙げられる。炭水化物の他の例には、トウモロコシデンプン加水分解物、マルトデキストリン、グルコースポリマー、スクロース、マルトース、ラクトース、トウモロコシシロップ、固体トウモロコシシロップ、グルコース、フルクトース、高フルクトーストウモロコシシロップ、および消化不能オリゴ糖、例えばフルクトオリゴ糖(FOS)が挙げられる。上に挙げたいずれか1つ炭水化物、または適切な場合にはこれらのあらゆる組合せを利用することができる。他の適する炭水化物は、当業者には容易にわかることだろう。上で述べたように、本栄養製品中の炭水化物の典型的な量は、全カロリーの約10%から約95%、さらに好ましくは全カロリーの約15%から約90%である。
表3は、1,000キログラムの本発明の未着香液体栄養製品を製造するための材料表を提示するものである。この製造の詳細な説明は、後述する。
実施例Aで説明した栄養製品の代替製品形態は、半個体またはプディングである。この製品は、次のことを加えて、加熱処理および均質化段階まで実施例Aの場合のように製造する。2つの追加のデンプン(イリノイ州、ディケーターのA.E.Staleyにより、ResistaおよびMiraclearの製品名で配給されているもの)を、製品の全固形分の4.5重量/重量%で、炭水化物スラリーに添加する。水溶性ビタミンおよび任意の香味を未希釈のブレンドに添加する。このプディングを全固形分約30重量/重量%から32重量/重量%で適切な容器に充填し、最後に滅菌する。または、このプディングを適切な容器に無菌充填する。
実施例Aで説明した栄養製品のもう一つの製品形態は、粉末である。本製品は、加熱処理および均質化段階まで実施例Aの場合のように製造する。水溶性ビタミンおよび任意の香味を未希釈のブレンドに添加する。このブレンドを、全固形分約45%から55%で塔式乾燥機にポンプ輸送する。典型的な乾燥機のパラメータは次のとおりである:ノズル圧は、1400から2400ゲージpsigであり、液体流量は、最大10gpmであり、流入空気温は、最高211℃であり、流出空気温は、87から104℃であり、乾燥室圧は、水の−0.2から+0.2インチである。
本発明の栄養製品は、栄養バーとして配合することもできる。如何なる点においても本発明を限定するつもりはないが、単に一般的な指針として、栄養バーのための典型的は配合を表4に記載する。
MUFAおよびω−3 PUFAが豊富な配合物が、糖の調節およびインスリン感受性、ならびにNIDDM/インスリン抵抗性の定着した動物モデルにおける血管機能を改善することができるかどうかを判定するために試験を行った。
第二の試験は、一不飽和脂肪酸が豊富な配合物およびω−3 PUFAを補足した一不飽和脂肪酸が豊富な配合物での食事介入が、インスリン非依存性糖尿病のマウスモデルにおいて血管機能を改善することができるかどうかを判定するために行った。単離された大動脈輪において内皮依存性血管作用剤、カルバコールが弛緩を誘導する能力を判定した。雄ob/obマウスおよびこれらの痩身の同腹子の6つのグループに実験食を4週間与えた。マウスは、上の実験Iで説明した仕方と同じ要領で保持した。比較のために、ob/obマウスのグループおよびこれらの痩身の同腹子のグループに標準的なエサの食事を与えた。実験1の場合のように、Glucerna(登録商標)OS(オハイオ州、コロンバスのRoss Products Division,Abbott Laboratories)組成物をこの試験の基本配合物として使用し、実験配合物を8オンス缶で調製した。脂肪の量を増加し、表9に記載する脂質系を配合することにより、Glucerna(登録商標)OSを変性した。
Claims (45)
- α−リノレイン酸(C18:3n−3)、ω−6脂肪酸およびω−9脂肪酸を含み、
前記ω−6脂肪酸の前記α−リノレイン酸(C18:3n−3)に対する比率が、約0.25:1から約3:1であり、ならびに
前記ω−9脂肪酸の前記α−リノレイン酸(C18:3n−3)に対する比率が、約0.4:1から約3:1である脂質系。 - 前記ω−6脂肪酸の前記α−リノレイン酸(C18:3n−3)に対する比率が、約0.3:1から約2.5:1である、請求項1に記載の脂質系。
- 前記ω−9脂肪酸の前記α−リノレイン酸(C18:3n−3)に対する比率が、約1:1から約3:1である、請求項1に記載の脂質系。
- 炭素原子数が12より多い飽和脂肪酸をさらに含み、前記飽和脂肪酸が、脂質100gあたり約47g未満の量で存在する、請求項1に記載の脂質系。
- 前記ω−6脂肪酸が、リノール酸(C18:2n−6)、γ−リノレイン酸(C18:3n−6)、エイコサジエン酸(C20:2n−6)、アラキドン酸(C20:4n−6)、ジ−ホモ−γ−リノレイン酸(C20:3n−6)、およびこれらの組合せから成る群より選択される、請求項1に記載の脂質系。
- 前記ω−9脂肪酸が、オレイン酸(C18:1n−9)、エライジン酸(C18:1n−9)、エイコセン酸(C20:1n−9)、エルカ酸(C22:1n−9)およびネルボン酸(C24:1n−9)、ならびにこれらの組合せから成る群より選択される、請求項1に記載の脂質系。
- 脂質系の全重量を基準にして、約17から約54%のα−リノレイン酸(C18:3n−3)、約17から約21%のリノール酸(C18:2n−6)、約19から約52%のオレイン酸(C18:1n−9)、および約47%未満の飽和脂肪酸を含む、請求項1に記載の脂質系。
- 約30から約90%のアマニ油、約0から約59%の高オレイン酸ベニバナ油、および約0から約7%のトウモロコシ油を含む、請求項1に記載の脂質系。
- 液体栄養製品、固体栄養製品、半固体栄養製品、乳濁液として提供される製品、粉末として提供される製品、およびソフトゼラチンカプセルとして提供される製品から成る群より選択される、請求項1に記載の脂質系を含む製品。
- 請求項1に記載の脂質系を投与することを含む、糖不耐性の個体の耐糖能を改善するための方法。
- 請求項1に記載の脂質系を投与することを含む、インスリン抵抗性の個体のインスリン感受性を改善するための方法。
- 請求項1に記載の脂質系を投与することを含む、血管疾患の危険性のある個体において血管疾患の危険性を低減するための方法。
- 請求項9に記載の栄養製品を投与することを含む、個体に栄養を提供するための方法。
- a)α−リノレイン酸(C18:3n−3)、ω−6脂肪酸およびω−9脂肪酸を含み、
i)前記ω−6脂肪酸の前記α−リノレイン酸(C18:3n−3)に対する比率が、0.25:1と3:1の間であり、および
ii)前記ω−9脂肪酸の前記α−リノレイン酸(C18:3n−3)に対する比率が、0.4:1と3:1の間である脂質系、ならびに
b)全カロリー量の約5から約35%を提供する蛋白質成分、全カロリー量の約10から約95%を提供する炭水化物、および全カロリー量の約5から約70%を提供する脂質成分
を含む、栄養製品。 - 前記ω−6脂肪酸の前記α−リノレイン酸(C18:3n−3)に対する比率が、約0.3:1から約2.5:1である、請求項14に記載の栄養製品。
- 前記ω−9脂肪酸の前記α−リノレイン酸(C18:3n−3)に対する比率が、約1:1から約3:1である、請求項14に記載の栄養製品。
- 炭素原子数が12より多い飽和脂肪酸をさらに含み、前記飽和脂肪酸が、脂質100gあたり47g未満の量で存在する、請求項14に記載の栄養製品。
- 前記ω−6脂肪酸が、リノール酸(C18:2n−6)、γ−リノレイン酸(C18:3n−6)、エイコサジエン酸(C20:2n−6)、アラキドン酸(C20:4n−6)、ジ−ホモ−γ−リノレイン酸(C20:3n−6)、およびこれらの組合せから成る群より選択され、ならびに前記ω−9脂肪酸が、オレイン酸(C18:1n−9)、エライジン酸(C18:1n−9)、エイコセン酸(C20:1n−9)、エルカ酸(C22:1n−9)およびネルボン酸(C24:1n−9)、ならびにこれらの組合せから成る群より選択される、請求項14に記載の栄養製品。
- 約17から約54%のα−リノレイン酸(C18:3n−3)、約17から約21%のリノール酸(C18:2n−6)、約19から約52%のオレイン酸(C18:1n−9)、および約47%未満の飽和脂肪酸を含む、請求項14に記載の栄養製品。
- 約30から約90%のアマニ油、約0から約59%の高オレイン酸ベニバナ油、および約0から約7%のトウモロコシ油を含む、請求項14に記載の栄養製品。
- 請求項14に記載の栄養製品を投与することを含む、糖不耐性の個体の耐糖能を改善するための方法。
- 請求項14に記載の栄養製品を投与することを含む、インスリン抵抗性の個体のインスリン感受性を改善するための方法。
- 請求項14に記載の栄養製品を投与することを含む、血管疾患の危険性のある個体において血管疾患の危険性を低減するための方法。
- 請求項14に記載の栄養製品を投与することを含む、個体に栄養を提供するための方法。
- ω−3脂肪酸、ω−6脂肪酸およびω−9脂肪酸を含み、
前記ω−6脂肪酸の前記ω−3脂肪酸に対する比率が、0.25:1と3:1の間であり、および
前記ω−9脂肪酸の前記ω−3脂肪酸に対する比率が、0.4:1と3:1の間である脂質系を、糖不耐性の個体に投与することを含む、糖不耐性の個体の耐糖能を改善するための方法。 - 前記ω−6脂肪酸の前記ω−3脂肪酸に対する比率が、0.3:1と2.5:1の間である、請求項25に記載の方法。
- 前記ω−9脂肪酸の前記ω−3脂肪酸に対する比率が、1:1と3:1の間である、請求項25に記載の方法。
- 前記ω−3脂肪酸が、α−リノレイン酸(C18:3n−3)、ステアリドン酸(C18:4n−3)、エイコサペンタエン酸(C20:5n−3)、ドコサペンタエン酸(C22:5n−3)、ドコサヘキサエン酸(C22:6n−3)、およびこれらの組合せから成る群より選択され、前記ω−6脂肪酸が、リノール酸(C18:2n−6)、γ−リノレイン酸(C18:3n−6)、エイコサジエン酸(C20:2n−6)、アラキドン酸(C20:4n−6)、ジ−ホモ−γ−リノレイン酸(C20:3n−6)、およびこれらの組合せから成る群より選択され、ならびに前記ω−9脂肪酸が、オレイン酸(C18:1n−9)、エライジン酸(C18:1n−9)、エイコセン酸(C20:1n−9)、エルカ酸(C22:1n−9)およびネルボン酸(C24:1n−9)、ならびにこれらの組合せから成る群より選択される、請求項25に記載の方法。
- 前記脂質系が、約17から約54%のα−リノレイン酸(C18:3n−3)、約17から約21%のリノール酸(C18:2n−6)、約19から約52%のオレイン酸(C18:1n−9)、および約47%未満の飽和脂肪酸を含む、請求項25に記載の方法。
- 前記脂質系が、約30から約90%のアマニ油、約0から約59%の高オレイン酸ベニバナ油、および約0から約7%のトウモロコシ油を含む、請求項25に記載の方法。
- ω−3脂肪酸、ω−6脂肪酸およびω−9脂肪酸を含み、
前記ω−6脂肪酸の前記ω−3脂肪酸に対する比率が、0.25:1と3:1の間であり、および
前記ω−9脂肪酸の前記ω−3脂肪酸に対する比率が、0.4:1と3:1の間である脂質系を、インスリン抵抗性の個体に投与することを含む、インスリン抵抗性の個体のインスリン感受性を改善するための方法。 - 前記ω−6脂肪酸の前記ω−3脂肪酸に対する比率が、0.3:1と2.5:1の間である、請求項31に記載の方法。
- 前記ω−9脂肪酸の前記ω−3脂肪酸に対する比率が、1:1と3:1の間である、請求項31に記載の方法。
- 前記ω−3脂肪酸が、α−リノレイン酸(C18:3n−3)、ステアリドン酸(C18:4n−3)、エイコサペンタエン酸(C20:5n−3)、ドコサペンタエン酸(C22:5n−3)、ドコサヘキサエン酸(C22:6n−3)、およびこれらの組合せから成る群より選択され、前記ω−6脂肪酸が、リノール酸(C18:2n−6)、γ−リノレイン酸(C18:3n−6)、エイコサジエン酸(C20:2n−6)、アラキドン酸(C20:4n−6)、ジ−ホモ−γ−リノレイン酸(C20:3n−6)、およびこれらの組合せから成る群より選択され、ならびに前記ω−9脂肪酸が、オレイン酸(C18:1n−9)、エライジン酸(C18:1n−9)、エイコセン酸(C20:1n−9)、エルカ酸(C22:1n−9)およびネルボン酸(C24:1n−9)、ならびにこれらの組合せから成る群より選択される、請求項31に記載の方法。
- 前記脂質系が、約17から約54%のα−リノレイン酸(C18:3n−3)、約17から約21%のリノール酸(C18:2n−6)、約19から約52%のオレイン酸(C18:1n−9)、および約47%未満の飽和脂肪酸を含む、請求項31に記載の方法。
- 前記脂質系が、約30から約90%のアマニ油、約0から約59%の高オレイン酸ベニバナ油、約0から約7%のトウモロコシ油、および約0から約7%の大豆レシチンを含む、請求項31に記載の方法。
- ω−3脂肪酸、ω−6脂肪酸およびω−9脂肪酸を含み、
前記ω−6脂肪酸の前記ω−3脂肪酸に対する比率が、0.25:1と3:1の間であり、および
前記ω−9脂肪酸の前記ω−3脂肪酸に対する比率が、0.4:1と3:1の間である脂質系を、血管疾患の危険性のある個体に投与することを含む、血管疾患の危険性のある個体において血管疾患の危険性を低減するための方法。 - 前記ω−6脂肪酸の前記ω−3脂肪酸に対する比率が、0.3:1と2.5:1の間である、請求項37に記載の方法。
- 前記ω−9脂肪酸の前記ω−3脂肪酸に対する比率が、1:1と3:1の間である、請求項37に記載の方法。
- 前記ω−3脂肪酸が、α−リノレイン酸(C18:3n−3)、ステアリドン酸(C18:4n−3)、エイコサペンタエン酸(C20:5n−3)、ドコサペンタエン酸(C22:5n−3)、ドコサヘキサエン酸(C22:6n−3)、およびこれらの組合せから成る群より選択され、前記ω−6脂肪酸が、リノール酸(C18:2n−6)、γ−リノレイン酸(C18:3n−6)、エイコサジエン酸(C20:2n−6)、アラキドン酸(C20:4n−6)、ジ−ホモ−γ−リノレイン酸(C20:3n−6)、およびこれらの組合せから成る群より選択され、ならびに前記ω−9脂肪酸が、オレイン酸(C18:1n−9)、エライジン酸(C18:1n−9)、エイコセン酸(C20:1n−9)、エルカ酸(C22:1n−9)およびネルボン酸(C24:1n−9)、ならびにこれらの組合せから成る群より選択される、請求項37に記載の方法。
- 前記脂質系が、約17から約54%のα−リノレイン酸(C18:3n−3)、約17から約21%のリノール酸(C18:2n−6)、約19から約52%のオレイン酸(C18:1n−9)、および約47%未満の飽和脂肪酸を含む、請求項37に記載の方法。
- 前記脂質系が、約30から約90%のアマニ油、約0から約59%の高オレイン酸ベニバナ油、および約0から約7%のトウモロコシ油を含む、請求項37に記載の方法。
- 前記血管疾患の危険性が、血管機能障害である、請求項37に記載の方法。
- 前記血管機能障害が、血管拡張障害、血流低下および高血圧から成る群より選択される、請求項43に記載の方法。
- 前記血管疾患の危険性が、血中脂質レベル上昇である、請求項43に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/656,662 | 2003-09-05 | ||
US10/656,662 US7759507B2 (en) | 2003-09-05 | 2003-09-05 | Lipid system and methods of use |
PCT/US2004/025161 WO2005025334A1 (en) | 2003-09-05 | 2004-08-04 | Lipid system and methods of use |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007504225A true JP2007504225A (ja) | 2007-03-01 |
JP2007504225A5 JP2007504225A5 (ja) | 2015-05-21 |
JP5745734B2 JP5745734B2 (ja) | 2015-07-08 |
Family
ID=34226392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006525335A Expired - Fee Related JP5745734B2 (ja) | 2003-09-05 | 2004-08-04 | 脂質系および使用方法 |
Country Status (13)
Country | Link |
---|---|
US (2) | US7759507B2 (ja) |
EP (1) | EP1662905A1 (ja) |
JP (1) | JP5745734B2 (ja) |
KR (1) | KR20060076766A (ja) |
CN (1) | CN1874692B (ja) |
AU (2) | AU2004271928B2 (ja) |
BR (1) | BRPI0414096A (ja) |
CA (1) | CA2536692C (ja) |
IL (1) | IL173967A (ja) |
MX (1) | MXPA06002481A (ja) |
NZ (1) | NZ545470A (ja) |
WO (1) | WO2005025334A1 (ja) |
ZA (1) | ZA200602768B (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009219500A (ja) * | 2009-06-22 | 2009-10-01 | Suntory Holdings Ltd | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
JP2010166891A (ja) * | 2009-01-26 | 2010-08-05 | Kaneka Corp | 水中油型乳化油脂組成物 |
JP2014505702A (ja) * | 2011-02-02 | 2014-03-06 | ネステク ソシエテ アノニム | 高タンパク質栄養組成物並びにその製造方法及び使用方法 |
JP2015118942A (ja) * | 2009-03-27 | 2015-06-25 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーE.I.Du Pont De Nemours And Company | 誘電伝熱流体 |
JP2015130867A (ja) * | 2009-04-24 | 2015-07-23 | モンサント テクノロジー エルエルシー | オメガ3強化シリアル、グラノーラ、およびスナックバー |
JP2015530981A (ja) * | 2012-07-31 | 2015-10-29 | ネステク ソシエテ アノニム | 炎症性腸疾患(ibd)患者の筋骨格の健康を促進させるための栄養組成物 |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7344747B2 (en) * | 2004-04-29 | 2008-03-18 | Gfa Brands, Inc. | Oxidative stabilization of omega-3 fatty acids in low linoleic acid-containing peanut butter |
US20060083824A1 (en) * | 2004-10-20 | 2006-04-20 | Pbm Products Llc | Nutritional supplements for glucose intolerant individuals |
MX2008001282A (es) * | 2005-07-28 | 2008-03-24 | Reliant Pharmaceuticals Inc | Tratamiento con bloqueadores del canal del calcio de dihidropiridina y acidos grasos omega-3 y un producto de combinacion de los mismos. |
US20070166411A1 (en) * | 2005-12-16 | 2007-07-19 | Bristol-Myers Squibb Company | Nutritional supplement containing long-chain polyunsaturated fatty acids |
WO2007132888A1 (ja) * | 2006-05-16 | 2007-11-22 | National Institute Of Advanced Industrial Science And Technology | 平滑筋収縮抑制剤 |
CA2673957C (en) * | 2006-12-28 | 2011-10-11 | The Nisshin Oillio Group, Ltd. | Oil-and-fat composition, and food or beverage containing the oil-and-fat composition |
WO2008085019A1 (en) * | 2007-01-11 | 2008-07-17 | Carotino Sdn. Bhd. | A method for lowering risk of cardiovascular diseases |
US20080207748A1 (en) * | 2007-02-22 | 2008-08-28 | Innovation Labs, Inc. | Vitamin c preparation |
US20080269328A1 (en) * | 2007-04-09 | 2008-10-30 | Mohammed Moghadasian | Effects of low n-6:n-3 fatty acid ratio from two dietary sources on plasma and tissue lipid composition |
EP2211881A4 (en) * | 2007-11-01 | 2012-01-04 | Wake Forest University School Of Medicine | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DISEASES AFFECTING MAMMALS |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
US20090155447A1 (en) * | 2007-12-12 | 2009-06-18 | Solae, Llc | Protein extrudates comprising omega-3 fatty acids |
US20110177224A1 (en) * | 2008-03-03 | 2011-07-21 | Daniel Perlman | Stabilization of omega-3 fatty acids in oil-water emulsions |
US20090264520A1 (en) * | 2008-04-21 | 2009-10-22 | Asha Lipid Sciences, Inc. | Lipid-containing compositions and methods of use thereof |
WO2010040012A1 (en) * | 2008-10-01 | 2010-04-08 | Martek Biosciences Corporation | Compositions and methods for reducing triglyceride levels |
US9480670B2 (en) * | 2009-04-01 | 2016-11-01 | Nestec S.A. | Reduction of risk of obesity |
US11986508B1 (en) | 2010-04-06 | 2024-05-21 | Juliana Konzny | Nutritional and cosmetic product, system and method for use |
CN101843336A (zh) * | 2010-04-22 | 2010-09-29 | 王京南 | 亚麻油脂肪乳口服溶液、饮料及制造方法 |
US10682327B2 (en) | 2011-04-17 | 2020-06-16 | Omega Foods, LLC | Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids |
US20210176999A1 (en) | 2011-04-17 | 2021-06-17 | Omega Foods, LLC | Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids |
US10653160B2 (en) | 2011-04-17 | 2020-05-19 | Omega Foods, LLC | Prepared foods having high efficacy omega 6/omega 3 balanced polyunsaturated fatty acids |
CA2857372C (en) * | 2011-04-17 | 2021-07-06 | Omega Foods, LLC | Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids |
WO2012145119A2 (en) * | 2011-04-17 | 2012-10-26 | Michael Gurin | Low inflammatory blended oils |
BR112014016788A8 (pt) | 2012-01-06 | 2017-07-04 | Chrysalis Pharma Ag | composições de ácidos graxos poli-insaturados ômega-3 em forma de ácido livre, enriquecidas com dpa |
US8551551B2 (en) | 2012-01-06 | 2013-10-08 | Perlman Consulting, Llc | Stabilization of omega-3 fatty acids in saturated fat microparticles having low linoleic acid content |
EP2846779A4 (en) | 2012-05-07 | 2015-12-16 | Omthera Pharmaceuticals Inc | STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS |
WO2013186233A1 (en) * | 2012-06-12 | 2013-12-19 | Norwegian University Of Science And Technology | Composition |
CN104247787A (zh) * | 2013-06-26 | 2014-12-31 | 孙志刚 | 一种正营养动植物油混合普健康经济型a级双合食用油 |
CN104247786A (zh) * | 2013-06-26 | 2014-12-31 | 孙志刚 | 一种正营养动植物油混合健康双合食用油 |
CN104413168A (zh) * | 2013-08-20 | 2015-03-18 | 孙志刚 | 一种日摄入量30-35克人群24种正营养食用油各种健康指标的脂肪酸科学配比 |
CN104413167A (zh) * | 2013-08-20 | 2015-03-18 | 孙志刚 | 一种日摄入量35克以上人群24种正营养食用油各种健康指标的脂肪酸科学配比 |
CN104413170A (zh) * | 2013-08-20 | 2015-03-18 | 孙志刚 | 一种日摄入量25-30克人群24种正营养食用油各种健康指标的脂肪酸科学配比 |
EP3190099B1 (de) | 2015-09-14 | 2020-10-28 | Helmholtz-Zentrum Potsdam - Deutsches GeoForschungsZentrum GFZ Stiftung des Öffentlichen Rechts des Lands Brandenburg | Neue fettsäure und ihre verwendung |
BR102016016559A2 (pt) * | 2016-07-18 | 2018-02-06 | Francisco Pianowski Luiz | Apresentação de cloreto de magnésio ingerível |
WO2024047075A1 (en) * | 2022-09-01 | 2024-03-07 | Universität Zürich | Lipid emulsion with anti-inflammatory effects for total parenteral and enteral nutrition |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07507327A (ja) * | 1992-07-27 | 1995-08-10 | アボツト・ラボラトリーズ | 神経系損傷を有するヒトのための栄養製剤 |
EP0682879A1 (de) * | 1994-05-20 | 1995-11-22 | HEIRLER, Horst | Diätetisches Lebensmittel mit mittelkettigen Fettsäuren und dessen Verwendung |
JP2000157170A (ja) * | 1998-11-26 | 2000-06-13 | Nisshin Oil Mills Ltd:The | 食用油 |
WO2002024180A2 (en) * | 2000-09-21 | 2002-03-28 | Nutrition 21, Inc. | Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
US20030130346A1 (en) * | 2001-06-25 | 2003-07-10 | Horst Heirler | Use of medium-chain triglycerides for the prevention and therapy of adiposity |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8302708D0 (en) * | 1983-02-01 | 1983-03-02 | Efamol Ltd | Pharmaceutical and dietary composition |
US4526902A (en) * | 1983-10-24 | 1985-07-02 | Century Laboratories, Inc. | Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions |
US4921877A (en) * | 1986-10-27 | 1990-05-01 | Abbott Laboratories | Liquid nutritional formula for glucose intolerance |
GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
US6140304A (en) * | 1988-09-28 | 2000-10-31 | Eicotech Corporation | Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia |
US5059622A (en) * | 1989-08-29 | 1991-10-22 | Biosyn, Inc. | Method for reducing blood pressure levels in hypertensive persons |
GB2223943A (en) | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
US5922345A (en) * | 1990-12-07 | 1999-07-13 | Scotia Holdings Plc | Nutrition |
JPH0745616A (ja) * | 1993-07-29 | 1995-02-14 | Nec Corp | 半導体装置の製造方法 |
EP0937408B1 (fr) | 1993-08-20 | 2004-02-11 | Societe Des Produits Nestle S.A. | Produit laitier comprenant une composition lipidique nutritionnelle |
US5952314A (en) * | 1994-04-01 | 1999-09-14 | Demichele; Stephen Joseph | Nutritional product for a person having ulcerative colitis |
DE69525150T2 (de) | 1994-04-01 | 2002-09-05 | Abbott Lab | Nahrungsprodukt zur behandlung der ulzerativen kolitis sowie verwendung desselben |
US5780451A (en) * | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
JP3840670B2 (ja) | 1995-01-27 | 2006-11-01 | 味の素株式会社 | 糖尿病患者用脂肪輸液剤 |
US5895652A (en) * | 1996-07-29 | 1999-04-20 | Longevity Institute International | Method of metabolic adjuvanation and cellular repair |
US5922704A (en) * | 1997-12-24 | 1999-07-13 | Feeling Fine Company Llc | Optimal nutritional supplement for men |
EP1082028B1 (en) | 1998-06-03 | 2002-05-15 | The State Of Israel-Ministry Of Agriculture | Matthiola seed oil, mixtures containing it and use thereof |
AU5678699A (en) | 1998-08-27 | 2000-03-21 | Bowles Fluidics Corporation | Water bottle with drinking and spray modes |
AUPQ228199A0 (en) | 1999-08-18 | 1999-09-09 | Sly, Anthony William | Ophthalmic fluid |
JP4391673B2 (ja) * | 2000-08-08 | 2009-12-24 | 花王株式会社 | 油脂組成物 |
DE60143753D1 (de) | 2000-08-08 | 2011-02-10 | Kao Corp | Öl-/fett-zusammensetzung |
WO2002017903A1 (en) | 2000-08-26 | 2002-03-07 | Metagenics, Inc. | Improved stability conjugated linoleic acid composition for dietary supplement and food uses |
CN1339262A (zh) | 2001-09-21 | 2002-03-13 | 阮生 | 食用香油 |
-
2003
- 2003-09-05 US US10/656,662 patent/US7759507B2/en not_active Expired - Fee Related
-
2004
- 2004-08-04 JP JP2006525335A patent/JP5745734B2/ja not_active Expired - Fee Related
- 2004-08-04 BR BRPI0414096-6A patent/BRPI0414096A/pt not_active Application Discontinuation
- 2004-08-04 WO PCT/US2004/025161 patent/WO2005025334A1/en active Application Filing
- 2004-08-04 AU AU2004271928A patent/AU2004271928B2/en not_active Ceased
- 2004-08-04 EP EP04780062A patent/EP1662905A1/en not_active Withdrawn
- 2004-08-04 MX MXPA06002481A patent/MXPA06002481A/es active IP Right Grant
- 2004-08-04 KR KR1020067004508A patent/KR20060076766A/ko not_active Application Discontinuation
- 2004-08-04 NZ NZ545470A patent/NZ545470A/en not_active IP Right Cessation
- 2004-08-04 CN CN200480032634XA patent/CN1874692B/zh not_active Expired - Fee Related
- 2004-08-04 CA CA2536692A patent/CA2536692C/en not_active Expired - Fee Related
-
2006
- 2006-02-27 IL IL173967A patent/IL173967A/en not_active IP Right Cessation
- 2006-04-04 ZA ZA200602768A patent/ZA200602768B/en unknown
-
2007
- 2007-10-25 US US11/923,889 patent/US7601757B2/en not_active Expired - Fee Related
-
2011
- 2011-04-01 AU AU2011201489A patent/AU2011201489A1/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07507327A (ja) * | 1992-07-27 | 1995-08-10 | アボツト・ラボラトリーズ | 神経系損傷を有するヒトのための栄養製剤 |
EP0682879A1 (de) * | 1994-05-20 | 1995-11-22 | HEIRLER, Horst | Diätetisches Lebensmittel mit mittelkettigen Fettsäuren und dessen Verwendung |
JP2000157170A (ja) * | 1998-11-26 | 2000-06-13 | Nisshin Oil Mills Ltd:The | 食用油 |
WO2002024180A2 (en) * | 2000-09-21 | 2002-03-28 | Nutrition 21, Inc. | Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
US20030130346A1 (en) * | 2001-06-25 | 2003-07-10 | Horst Heirler | Use of medium-chain triglycerides for the prevention and therapy of adiposity |
Non-Patent Citations (5)
Title |
---|
CSNC201100690033; 佃克則、外1名: 日本臨床 , 2002, Vol. 60, Suppl 9 * |
JPN6011001008; 南麻子、外4名: 'エイコサペンタエン酸は血中トリグリセライド濃度を低下させ内臓脂肪肥満ラットのインスリン抵抗性を改善す' 動脈硬化 Vol. 27, No. 6, 20000420, p. 133-139 * |
JPN6011001009; 坂本貞一、外5名: 'NIDDMモデルラット、OLETFのインスリン抵抗性に対するイコサペンタエン酸とオレイン酸の影響' 第53回日本栄養・食糧学会大会講演要旨集 , 19990420, p. 35 * |
JPN6012054327; 佃克則、外1名: 日本臨床 , 2002, Vol. 60, Suppl 9 |
JPN6012054329; 井手隆: 日本農芸化学会大会講演要旨集 第71巻臨時増刊号, 1997, p.30, 社団法人日本農芸化学会 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010166891A (ja) * | 2009-01-26 | 2010-08-05 | Kaneka Corp | 水中油型乳化油脂組成物 |
JP2015118942A (ja) * | 2009-03-27 | 2015-06-25 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーE.I.Du Pont De Nemours And Company | 誘電伝熱流体 |
JP2015130867A (ja) * | 2009-04-24 | 2015-07-23 | モンサント テクノロジー エルエルシー | オメガ3強化シリアル、グラノーラ、およびスナックバー |
JP2009219500A (ja) * | 2009-06-22 | 2009-10-01 | Suntory Holdings Ltd | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
JP2014505702A (ja) * | 2011-02-02 | 2014-03-06 | ネステク ソシエテ アノニム | 高タンパク質栄養組成物並びにその製造方法及び使用方法 |
JP2015530981A (ja) * | 2012-07-31 | 2015-10-29 | ネステク ソシエテ アノニム | 炎症性腸疾患(ibd)患者の筋骨格の健康を促進させるための栄養組成物 |
Also Published As
Publication number | Publication date |
---|---|
KR20060076766A (ko) | 2006-07-04 |
CN1874692B (zh) | 2011-10-19 |
AU2004271928B2 (en) | 2011-04-14 |
IL173967A (en) | 2012-04-30 |
NZ545470A (en) | 2009-06-26 |
AU2004271928A1 (en) | 2005-03-24 |
BRPI0414096A (pt) | 2006-10-31 |
JP5745734B2 (ja) | 2015-07-08 |
AU2011201489A1 (en) | 2011-04-21 |
CN1874692A (zh) | 2006-12-06 |
WO2005025334A1 (en) | 2005-03-24 |
MXPA06002481A (es) | 2006-06-20 |
IL173967A0 (en) | 2006-07-05 |
EP1662905A1 (en) | 2006-06-07 |
US7759507B2 (en) | 2010-07-20 |
CA2536692A1 (en) | 2005-03-24 |
ZA200602768B (en) | 2007-09-26 |
US7601757B2 (en) | 2009-10-13 |
US20050054724A1 (en) | 2005-03-10 |
CA2536692C (en) | 2013-04-16 |
US20080039525A1 (en) | 2008-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5745734B2 (ja) | 脂質系および使用方法 | |
JP5572645B2 (ja) | ドコサヘキサエン酸およびルテインを含有する乳児用製剤 | |
US11297873B2 (en) | Ketogenic nutritional compositions | |
US9179702B2 (en) | Liquid nutritional compositions containing unsaturated fatty acids | |
US8173160B2 (en) | Compositions comprising edible oils and vitamins and/or minerals and methods for making the compositions | |
JP5816271B2 (ja) | 封入された油を含む栄養エマルジョン | |
CA2758889A1 (en) | High fiber nutritional emulsions | |
CA2758854A1 (en) | High fiber nutritional emulsions for blood glucose control | |
AU2010266593B2 (en) | Nut butter and related products enriched with omega-3 | |
US20070031538A1 (en) | Liquid nutritional compositions containing n-3 polyunsaturated fatty acids | |
JPH04152861A (ja) | 栄養補給用栄養組成物 | |
CA2758908A1 (en) | High fiber nutritional emulsions with glycerin | |
JPH07274825A (ja) | 易吸収性飲食品およびその製造法 | |
JP2003516946A (ja) | 消化管の適応の間における増殖応答を向上させる組成物および短腸症候群における使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070724 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070724 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110118 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110412 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110419 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110719 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120403 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20120802 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120814 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20121019 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140213 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141009 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141015 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141114 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141119 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141210 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141215 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20150114 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20150402 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150507 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5745734 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |